Jin-Woo Park, Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Sungwook Yu, Ji-Young Park
{"title":"<i>UGT2B15</i> single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans.","authors":"Jin-Woo Park, Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Sungwook Yu, Ji-Young Park","doi":"10.3389/fphar.2024.1507915","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly <i>UGT2B15</i>, has not been extensively explored in humans. This study aimed to investigate the effects of <i>UGT2B15</i>, <i>ABCB1</i>, and <i>CES1</i> polymorphisms on the pharmacokinetics of DAB and its acylglucuronide metabolites in healthy subjects.</p><p><strong>Methods: </strong>A total of 124 healthy males were genotyped for <i>UGT2B15</i>, <i>ABCB1</i>, and <i>CES1</i> polymorphisms. After a single 150 mg dose of DABE, plasma concentrations of total and free DAB, as well as dabigatran acylglucuronide (DABG) were measured using LC-MS/MS. Pharmacokinetic parameters were analyzed using non-compartmental methods, and statistical comparisons were conducted between the genotype groups.</p><p><strong>Results: </strong><i>UGT2B15</i> c.253G>T significantly affected free DAB pharmacokinetics, with a lower T<sub>max</sub> and oral clearance in TT genotype (n = 28, <i>p</i> < 0.05). For DABG, C<sub>max</sub> was significantly higher in GG genotypes (n = 32, 42.3 ± 16.3 ng/mL) compared to that in GT (n = 64, 32.4 ± 20.5 ng/mL) and TT (29.7 ± 17.1 ng/mL) genotypes. Similarly, the AUC<sub>all</sub> of DABG was highest in GG genotypes (327 ± 148.3 ng h·mL<sup>-1</sup>), followed by GT (238.7 ± 166.5 ng h·mL<sup>-1</sup>) and TT (223.3 ± 165.4 ng h·mL<sup>-1</sup>) genotypes (<i>p</i> < 0.05). The metabolite-to-parent ratios (m/p ratios) for C<sub>max</sub> and AUC<sub>all</sub> were significantly higher in GG and GT genotypes than that in TT genotype. <i>ABCB1</i> and <i>CES1</i> polymorphisms had no significant impact on the pharmacokinetics of DAB or DABG.</p><p><strong>Conclusion: </strong><i>UGT2B15</i> polymorphisms were associated with difference in DAB glucuronidation and pharmacokinetics in healthy male participants.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1507915"},"PeriodicalIF":4.8000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754044/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1507915","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Dabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly UGT2B15, has not been extensively explored in humans. This study aimed to investigate the effects of UGT2B15, ABCB1, and CES1 polymorphisms on the pharmacokinetics of DAB and its acylglucuronide metabolites in healthy subjects.
Methods: A total of 124 healthy males were genotyped for UGT2B15, ABCB1, and CES1 polymorphisms. After a single 150 mg dose of DABE, plasma concentrations of total and free DAB, as well as dabigatran acylglucuronide (DABG) were measured using LC-MS/MS. Pharmacokinetic parameters were analyzed using non-compartmental methods, and statistical comparisons were conducted between the genotype groups.
Results: UGT2B15 c.253G>T significantly affected free DAB pharmacokinetics, with a lower Tmax and oral clearance in TT genotype (n = 28, p < 0.05). For DABG, Cmax was significantly higher in GG genotypes (n = 32, 42.3 ± 16.3 ng/mL) compared to that in GT (n = 64, 32.4 ± 20.5 ng/mL) and TT (29.7 ± 17.1 ng/mL) genotypes. Similarly, the AUCall of DABG was highest in GG genotypes (327 ± 148.3 ng h·mL-1), followed by GT (238.7 ± 166.5 ng h·mL-1) and TT (223.3 ± 165.4 ng h·mL-1) genotypes (p < 0.05). The metabolite-to-parent ratios (m/p ratios) for Cmax and AUCall were significantly higher in GG and GT genotypes than that in TT genotype. ABCB1 and CES1 polymorphisms had no significant impact on the pharmacokinetics of DAB or DABG.
Conclusion: UGT2B15 polymorphisms were associated with difference in DAB glucuronidation and pharmacokinetics in healthy male participants.
期刊介绍：
Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
